Search Result

Results for "

OMP

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bacterial (1) Notch (4) Small Interfering RNA (siRNA) (1) Wnt (2)
By Research Areas:	Cancer (8) Infection (1) Metabolic Disease (1)
Oligonucleotides:	Pre-designed siRNA Sets (1) siRNAs (1)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99320

Tarextumab OMP 59R5; Anti-Human NOTCH2 Recombinant Antibody	Notch	Cancer
Tarextumab (OMP-59R5) is an anti-Notch2/3 fully human IgG2 monoclonal antibody. Tarextumab shows anti-tumor activity .

HY-P9974

Vantictumab OMP-18R5	Wnt	Cancer
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .

HY-P99667

Ipafricept 1 Publications Verification OMP-54F28; FZD8-Fc	Wnt	Cancer
Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .

HY-P99261

Demcizumab OMP 21M18; Human Anti-TNFRSF10B Recombinant Antibody	Notch	Cancer
Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models .

HY-P99258

Brontictuzumab OMP 52M51; Anti-Human NOTCH1 Recombinant Antibody	Notch	Cancer
Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma .

HY-146412

Vanin-1-IN-3	Others	Metabolic Disease
Vanin-1-IN-3 (OMP-7) is a vanin-1 inhibitor with an IC₅₀ of 0.038 μM .

HY-RS09784

OMP Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
OMP Human Pre-designed siRNA Set A contains three designed siRNAs for OMP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

OMP Human Pre-designed siRNA Set A OMP Human Pre-designed siRNA Set A

HY-P99377

Navicixizumab OMP-305B83; Anti-DLL4 Reference Antibody (navicixizumab)	Notch	Cancer
Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer .

HY-162672

Antibacterial agent 231	Bacterial	Infection
Antibacterial agent 231 (derivative 8) is an antimicrobial agent against multidrug-resistant Helicobacter pylori (H. pylori) with a minimum inhibitory concentration of 0.25–0.5 μg/mL. Antibacterial agent 231 directly targets the protein transposase subunit SecA and the outer membrane protein assembly factor BamD to inhibit the trafficking and assembly of bacterial outer membrane proteins (OMPs). Antibacterial agent 231 can be used to study the effects of antibiotic treatment on intestinal microbial balance .

Cat. No.	Product Name	Target	Research Area

HY-P99401

Rosmantuzumab OMP-131R10	Inhibitory Antibodies	Cancer
Rosmantuzumab (OMP-131R10) is an anti-R-spondin 3 (RSPO3) humanized monoclonal antibody. Rosmantuzumab can be used for the research of advanced telapsed and refractory solid tumors .

HY-P99949

Etigilimab OMP-313M32	Inhibitory Antibodies	Cancer
Etigilimab (OMP-313M32), a humanized IgG1 monoclonal antibody, blocks TIGIT interaction with PVR (CD155; poliovirus receptor) and inhibits downstream signalling with target cell killing .

HY-P99320

Tarextumab OMP 59R5; Anti-Human NOTCH2 Recombinant Antibody	Notch	Cancer
Tarextumab (OMP-59R5) is an anti-Notch2/3 fully human IgG2 monoclonal antibody. Tarextumab shows anti-tumor activity .

HY-P9974

Vantictumab OMP-18R5	Wnt	Cancer
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .

HY-P99667

Ipafricept 1 Publications Verification OMP-54F28; FZD8-Fc	Wnt	Cancer
Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .

HY-P99261

Demcizumab OMP 21M18; Human Anti-TNFRSF10B Recombinant Antibody	Notch	Cancer
Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models .

HY-P99258

Brontictuzumab OMP 52M51; Anti-Human NOTCH1 Recombinant Antibody	Notch	Cancer
Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma .

HY-P99876

Efaprinermin alfa OMP-336B11	Inhibitory Antibodies	Others
Efaprimermin alfa (OMP-336B11) is a human monoclonal antibody targeting TNFRSF18. Efaprimermin alfa is a GITR ligand-Fc fusion protein .

HY-P99377

Navicixizumab OMP-305B83; Anti-DLL4 Reference Antibody (navicixizumab)	Notch	Cancer
Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-P99949

Etigilimab OMP-313M32	Classification of Application Fields Disease Research Fields Cancer	Others
Etigilimab (OMP-313M32), a humanized IgG1 monoclonal antibody, blocks TIGIT interaction with PVR (CD155; poliovirus receptor) and inhibits downstream signalling with target cell killing .

HY-P9974

Vantictumab OMP-18R5	Classification of Application Fields Disease Research Fields Cancer	Wnt
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .

HY-P99667

Ipafricept 1 Publications Verification OMP-54F28; FZD8-Fc	Classification of Application Fields Disease Research Fields Cancer	Wnt
Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .

HY-P99261

Demcizumab OMP 21M18; Human Anti-TNFRSF10B Recombinant Antibody	Classification of Application Fields Disease Research Fields Cancer	Notch
Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models .

HY-P99258

Brontictuzumab OMP 52M51; Anti-Human NOTCH1 Recombinant Antibody	Classification of Application Fields Disease Research Fields Cancer	Notch
Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma .

HY-P99377

Navicixizumab OMP-305B83; Anti-DLL4 Reference Antibody (navicixizumab)	Classification of Application Fields Disease Research Fields Cancer	Notch
Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer .

Species:	Human (1) E.coli (1)
Tag:	His (2) Myc (1)
Source:	E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P73736

	*Olfactory Marker Protein/OMP* Protein, Human (His)** Olfactory marker protein; Olfactory neuronal-specific protein; OMP	Human	E. coli
	OMP Protein acts as a modulator in the olfactory signal-transduction cascade, finely tuning olfactory signaling processes. Interacting with BEX1 and BEX2, OMP suggests potential associations with proteins in cellular processes, emphasizing its multifaceted role in the intricate olfactory signal transduction network and implying broader involvement in the molecular framework of olfactory function. Olfactory Marker Protein/OMP Protein, Human (His) is the recombinant human-derived Olfactory Marker protein/OMP protein, expressed by E. coli , with N-His labeled tag. The total length of Olfactory Marker Protein/OMP Protein, Human (His) is 163 a.a., with molecular weight of ~19 kDa.

HY-P71515

	BamA Protein, E.coli (Myc, His) bamA; yaeT; yzzN; yzzY; b0177; JW0172Outer membrane protein assembly factor BamA; OMP85	E.coli	E. coli
	BamA is a key member of the outer membrane protein assembly complex (Bam), which concentrates the assembly of β-barrel proteins into the outer membrane. Together with BamD, BamA forms the core mechanism of this process, which relies on the coordinated action of all five subunits. BamA Protein, E.coli (Myc, His) is the recombinant E. coli-derived BamA protein, expressed by E. coli , with N-10*His, C-Myc labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-RS09784

OMP Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
OMP Human Pre-designed siRNA Set A contains three designed siRNAs for OMP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

OMP

Inhibitors & Agonists

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Oligonucleotides

Natural
Products